Updated on 4 May 2015
In March 2015, Hospira's India plant was again faulted by the FDA with more than a dozen observations
Singapore: During its recent investor presentation, Hospira announced that the company had completed its evaluation of the corrective actions issued for the Rocky Mount Facility and the warning letter that had been issued by the FDA ‘has been lifted.'
This is good news for Pfizer which is buying Hospira for $17 billion, in a deal announced earlier this year. Hospira, however, has a lot of regulatory issues to clear up, with the company recently handed a warning letter earlier this month for its plant in Italy.
Pfizer execs have said they are thoroughly aware of the issues facing the company and are satisfied with the progress it is making. In March 2015, Hospira's India plant was again faulted by the FDA with more than a dozen observations.